All News

COVID,vaccinate,injection,green

Low COVID-19 Vaccine Risks in Rheumatic Patients

Jack Cush, MD

Data from the European Alliance of Associations for Rheumatology Coronavirus Vaccine registry shows that patients with with inflammatory or noninflammatory rheumatic and musculoskeletal disease have similar adverse event rates as the general public.

Read Article
myositis.jpg

Predicting Treatment Response in Inflammatory Muscle Disorders

MedPage Today

Rheumatologists looking for clues to whether their patients with certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study appearing in Arthritis Care & Research.

Read Article
CV,risk,MI,heart,cardiac

CV Risk Management in Rheumatic Disease Patients

Jack Cush, MD

The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.

Read Article
RheumNow Podcast square

Hand OA and Heroes in Rheumatology (2.11.2022)

Jack Cush, MD

Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.

Read Article
VitD_1.jpg

Vitamin D and the Risk of Autoimmune Diseases

Jack Cush, MD

The results of the VITAL study (presented at ACR 2021) are now published by BMJ, showing that vitamin D and omega 3 fatty acids reduce the overall risk of autoimmune disease (AID) in a population based intervention trial.

Read Article
RheumNow Podcast square

An Ounce of Prevention (2.4.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout. 

Read Article
144 SLE pts from the SLICC cohort were studied showing that a majority (61.2%) scores consistent with depression over 4 yrs; also an inconsistent association between disease activity and depression in multivariate analysis https://t.co/Js5jB6hlox

Links:

Dr. John Cush RheumNow ( View Tweet)

CSF aptamer (short nucleic acid sequences) discovery of neuropsychiatric lupus pts finds increase in few CSF proteins that are discriminatory -- CSF Lipocalin-2, M-CSF, IgM and complement C3, the latter assoc w/ acute confusional state. https://t.co/Mvp2U8DMh8

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult with moderate to severe, active, autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy.https://t.co/29HupHHOW6

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Challenges in Lupus: -Mortality greatest in 1st yr -Dx Delays 6.4 yrs -Long-term complications increased 50 fold -Steroids worsen long-term outcomes -Health care costs increased 3 to 5 years prior to Dx -Mean delay in drug starts after Dx =177 days https://t.co/ZMHTXBn4vm https://t.co/SX0fSxHoES

Links:

Dr. John Cush RheumNow ( View Tweet)
Predicting Treatment Response in Inflammatory Muscle Disorders Rheums looking for clues to whether their patients w/certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study in Arthritis Care & Research. https://t.co/kXFIEMTbkb https://t.co/UbO7nSsdAY

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 25/306 SLE patients (8.2%) who developed 29 episodes of Pulmonary Hemorrhage (PH). 1st manifestation . PH assoc w/ Renal dz, high SLE activity during PH; PH mortality w/ Renal failure & mech ventilation. https://t.co/ydJkgf5BFB

Links:

Dr. John Cush RheumNow ( View Tweet)

Challenges in Lupus: -Mortality greatest in 1st yr -Dx Delays 6.4 yrs -Long-term complications increased 50 fold -Steroids worsen long-term outcomes -Health care costs increased 3 to 5 years prior to Dx -Mean delay in drug starts after Dx =177 days https://t.co/QUbsIQtcRa https://t.co/zAMUp99ecg

Links:

Dr. John Cush RheumNow ( View Tweet)
Olumiant (baricitinib) studies in Lupus halted by Lilly due to mixed results in phase 3 trials. While the BRAVE-1 study showed 4-mg BARI meeting primary endpoint at 52 weeks; the Brave-II failed to do same & failed key secondary endpoints https://t.co/XBmo15UCYl

Links:

Dr. John Cush RheumNow ( View Tweet)

Lupus international cohort study of 1460 HCQ pts showed that SLE flares were increased with dose reduction (aHRs 1.20;CI 1.04 to 1.38) and HCQ discontinuation (aHR 1.56; 1.31 to 1.86), higher with low educational levels after HCQ D/C https://t.co/fO4fBtrFYo

Links:

Dr. John Cush RheumNow ( View Tweet)

Round up of last week's QD Clinics: -Steroid Weaning -Diagnosing Neuropsychiatric Lupus - Not the Same Ol’ Lecture - Your Next Follow-up Visit is When? QD Clinic is sponsored by RheumNow Live https://t.co/9U1wcbIMs4 https://t.co/HjyyGtbe4r

Links:

Dr. John Cush RheumNow ( View Tweet)
Among 10,205 admissions for psychosis, 19% were tested for ANA, 15% of those were ≥1:160; BUT ONLY 4 patients met 2019 ACR/EULAR criteria for SLE, & 2 met criteria for Neuropsychiatric SLE - NPSLE prevalence of 1.5% ANA+ psychosis pts https://t.co/r2sTSVKC66

Links:

Dr. John Cush RheumNow ( View Tweet)

Women Heroes in Rheum: - Barbara Ansell - JIA - Nanna Svartz - SSZ - Gertrude Elion - Nobel Prize for allopurinol, AZA - Tsai-Fan Yu - gout Rx - Mary Betty Stevens - lupus & vasculitis - Marian Ropes - 1st F ARA president - Fionula Brennan - TNFi & more https://t.co/a9tKUyWBBu https://t.co/UsHDpzJ8ma

Links:

Dr. John Cush RheumNow ( View Tweet)
A prospective study of 124 pediatric SLE pts from UK - estimated Incidence 0.36/100 000. In 1st year 71% on systemic steroids, 98.2% on immunosuppressives, 20.4% accruing damage (mostly neuropsychiatric); most needing multiple speciality team care https://t.co/wdh52pn1Fd

Links:

Dr. John Cush RheumNow ( View Tweet)

Psychosis is rare in SLE; Retrospective cohort review finds 18/709 SLE or 2.5% developed lupus psychosis. Psychosis remitted in 12/18 w/ a combo of antipsyschotic (in 38.9%) and immunosuppressive (steroid 72%, CTX 56%, RTX 17%, etc) https://t.co/AnCPaPS8QE

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×